Clinical trials: SARS-COV 2
COVID, SARS-CoV 2
Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19
No specific therapeutic agents or vaccines for COVID-19 are available. Several therapies, are under investigation, but the antiviral efficacy of these drugs is not yet known.
- Trial name
- TSUNAMI (NCT04393727)
- Testing
- CONVALESCENT PLASMA
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
SARS CoV 2 Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects
This is a phase I, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of ASC10 tablets and an open-label, crossover design to evaluate the food effect on PK of ASC10 in…
- Trial name
- NCT05523141
- Testing
- ASC10
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
COVID-19, SARS CoV 2 Infection
STREngthening COronavirus Disease 2019 (COVID-19) Surveillance in Africa
The aim of this observational study was to develop, with the intended users, an epidemic surveillance and response system that will be effective, sensitive, coordinated and appropriate.
- Conditions
- COVID-19, SARS CoV 2 Infection, COVID-19 Pandemic
- Trial name
- STREESCO (NCT06170320)
- Where
- Benin
- Volunteers
- 7,000 people
- Sponsor
- Institut de Recherche pour le Developpement
COVID-19, SARS-CoV 2
Trial to Promote Recovery From COVID-19 With Endocrine Therapy
Patients with COVID-19 requiring inpatient hospitalization will be randomized to treatment with standard of care or standard of care + bicalutamide.
- Trial name
- RECOVER (NCT04374279)
- Testing
- Bicalutamide 150 Mg Oral Tablet
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SARS-CoV 2
Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis
This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in the French population using serological tests and to assess the determinants of infection from Constances, E3N-E4N, ELFE-Epipage 2 and…
- Trial name
- SAPRIS-SERO (NCT04392388)
- Testing
- Non applicable
- Where
- France
- Volunteers
- 96,883 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
COVID-19, SARS-CoV 2
Tannin Specific Natural Extract for COVID-19 Infection
There is an urgent need to evaluate interventions that could be effective against the infection with SARS-CoV 2. Tannins based wood extracts are an inexpensive and safe product with protective effect in both bacterial and viral…
- Conditions
- COVID-19, SARS-CoV 2, Coronavirus Infection
- Trial name
- TanCOVID (NCT04403646)
- Testing
- ARBOX
- Where
- Argentina
- Volunteers
- 124 people
- Sponsor
- Hospital de Clinicas José de San Martín
SARS-CoV Infection, Covid19
Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19)
The pandemic caused by SARS-CoV-2 is a global emergency present in 6 continents including 66 countries, incurring a shortage of effective and safe therapeutic alternatives that can contribute to reducing the risk of…
- Conditions
- SARS-CoV Infection, Covid19, Infection Viral
- Trial name
- NCT04684550
- Testing
- Stabilized hypochlorous acid
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hospital Universitario San Ignacio
SARS-CoV 2
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction…
- Trial name
- NCT04405739
- Testing
- EIDD-2801
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Ridgeback Biotherapeutics, LP
Covid19
Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients
Severe ill Patients will be enrolled in the study (n=310) after duly filled consent forms. Recipients will be divided into 2 group, each group contain 155 patients to compare Safety and efficacy of patients in Clinical Trial…
- Trial name
- NCT04891172
- Testing
- Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)
- Where
- Pakistan
- Volunteers
- 310 people
- Sponsor
- Dow University of Health Sciences
SARS CoV 2 Infection, Pneumonia
SP16 as a Therapeutic for COVID-19 Induced ARDS
This randomized, double-blind, placebo-controlled, Phase 1b study evaluates the safety and tolerability, and effects on cytokine and acute phase reactants of SP16, an anti-inflammatory drug, in patients with pneumonia due to…
- Trial name
- NCT05135624
- Testing
- SP16 (6mg), SP16 (12 mg)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Serpin Pharma, LLC
Post Acute Sequelae of SARS CoV 2 Infection, Obstructive Sleep Apnea
Predictors of Post-COVID-19 Clinical and Cognitive Consequences
The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients.
- Trial name
- SCLC (NCT06291870)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Rheumatoid Arthritis, Spondyloarthritis
Vaccination Against SARS-Cov2 (COVID-19) in Chronic Inflammatory Rheumatism and Factors Determining Its Decision.
Rheumatoid arthritis and spondyloarthritis (ankylosing spondylitis and psoriatic arthritis mainly) are chronic inflammatory rheumatism (RIC), frequently onset in young adults. The prevalence is respectively 0.3 to 0.8% and 0.4%.
- Trial name
- VACCI-RIC (NCT04970550)
- Testing
- Non intervention
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Hopital Nord Franche-Comte
SARS-CoV 2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
- Trial name
- CSSC-004 (NCT04373460)
- Testing
- SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
- Where
- 29 sites in United States
- Volunteers
- 1,225 people
- Sponsor
- Johns Hopkins University
COVID, SARS Pneumonia
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
The trial evaluates the efficacy and safety of Tocilizumab, which rapidly reduces the inflammation process through inhibition of IL-6 in patients with moderate to severe COVID-19 with increased inflammatory markers.
- Conditions
- COVID, SARS Pneumonia, Cytokine Release Syndrome
- Trial name
- TOCIBRAS (NCT04403685)
- Testing
- Tocilizumab
- Where
- 7 sites in Brazil
- Volunteers
- 129 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Covid19, Corona Virus Infection
T Cells Response to SARS COV 2 Peptides
The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral…
- Trial name
- NCT04573348
- Testing
- Savicell's ImmunoBiopsy™
- Where
- Israel
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Savicell Diagnostics Ltd
SARS-CoV 2, COVID-19
Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19
Prospective study for clinical performance evaluation of COVID-19 diagnostic tests: detection of anti-SARS-CoV-2 antibodies by RDTs or ELISA (manual or automated), rapid diagnostic tests based on antigen detection, molecular or…
- Trial name
- ERap-COV (NCT04405492)
- Testing
- Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling., Capillary and salivary sampling
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV 2
Association Between BMI and COVID-19
This study will involve collection of pseudonymized data from hospital-based data reporting at multiple international sites. Collating data from a large volume of patients with COVID-19 admitted in ICU across multiple…
- Trial name
- BMI-SARS-CoV-2 (NCT04391738)
- Testing
- Patients admitted to Intensive Care Unit with SARS-CoV2
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- University Hospital, Lille
COVID-19
Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection
The risk for the development of complications from COVID-19 occurs mainly in patients over 65 years of age, with obesity, arterial hypertension, chronic lung diseases and immunosuppression states.
- Trial name
- NCT05089305
- Testing
- Ozone plasma
- Where
- 2 sites in Mexico
- Volunteers
- 35 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
COVID-19
Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2
The AstraZeneca Study is a single-arm, open-label, interventional, Phase 3b study to determine the incidence of laboratory-confirmed COVID-19 hospitalizations, disease severity, and deaths and attributable adverse events (AEs) in…
- Trial name
- NCT05715944
- Testing
- AZD 1222
- Where
- Botswana
- Volunteers
- 10,888 people, healthy volunteers welcome
- Sponsor
- Botswana Harvard AIDS Institute Partnership
SARS-CoV 2, COVID
SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the current pandemic of coronavirus disease (COVID-19) that can lead to respiratory failure requiring oxygen therapy.
- Trial name
- NCT04365595
- Testing
- Questionnaires, spirometry
- Where
- Switzerland
- Volunteers
- 58 people
- Sponsor
- University of Zurich